578 related articles for article (PubMed ID: 18281473)
1. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
2. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
[TBL] [Abstract][Full Text] [Related]
4. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US
Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.
Rice JC; Massey-Brown KS; Futscher BW
Oncogene; 1998 Oct; 17(14):1807-12. PubMed ID: 9778046
[TBL] [Abstract][Full Text] [Related]
7. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
[TBL] [Abstract][Full Text] [Related]
8. PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.
Kim JH; Choi DH; Cho DY; Ahn SH; Son BH; Haffty BG
Breast Cancer Res Treat; 2010 Jul; 122(1):303-6. PubMed ID: 20213081
[TBL] [Abstract][Full Text] [Related]
9. PALB2 analysis in BRCA2-like families.
Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
[TBL] [Abstract][Full Text] [Related]
10. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Apr; 114(3):457-62. PubMed ID: 18446436
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Kontorovich T; Cohen Y; Nir U; Friedman E
Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway.
Wang YQ; Zhang JR; Li SD; He YY; Yang YX; Liu XL; Wan XP
Cancer Sci; 2010 Jul; 101(7):1618-23. PubMed ID: 20487263
[TBL] [Abstract][Full Text] [Related]
14. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
15. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
Hellebrand H; Sutter C; Honisch E; Gross E; Wappenschmidt B; Schem C; Deissler H; Ditsch N; Gress V; Kiechle M; Bartram CR; Schmutzler RK; Niederacher D; Arnold N; Meindl A
Hum Mutat; 2011 Jun; 32(6):E2176-88. PubMed ID: 21618343
[TBL] [Abstract][Full Text] [Related]
16. A recurrent mutation in PALB2 in Finnish cancer families.
Erkko H; Xia B; Nikkilä J; Schleutker J; Syrjäkoski K; Mannermaa A; Kallioniemi A; Pylkäs K; Karppinen SM; Rapakko K; Miron A; Sheng Q; Li G; Mattila H; Bell DW; Haber DA; Grip M; Reiman M; Jukkola-Vuorinen A; Mustonen A; Kere J; Aaltonen LA; Kosma VM; Kataja V; Soini Y; Drapkin RI; Livingston DM; Winqvist R
Nature; 2007 Mar; 446(7133):316-9. PubMed ID: 17287723
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
Bean GR; Ibarra Drendall C; Goldenberg VK; Baker JC; Troch MM; Paisie C; Wilke LG; Yee L; Marcom PK; Kimler BF; Fabian CJ; Zalles CM; Broadwater G; Scott V; Seewaldt VL
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):50-6. PubMed ID: 17220331
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
19. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
Dammann R; Yang G; Pfeifer GP
Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
